Insider Transactions in Q2 2021 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2021
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
3,895
+50.0%
|
-
|
|
Jun 24
2021
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+21.8%
|
-
|
|
Jun 24
2021
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 24
2021
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.02%
|
-
|
|
Jun 24
2021
|
Lars Ekman Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 24
2021
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+14.58%
|
-
|
|
Jun 24
2021
|
William Aliski Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+3.11%
|
-
|
|
Jun 24
2021
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
2,145
+12.93%
|
-
|
|
Jun 21
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
572
-2.18%
|
$53,768
$94.96 P/Share
|
|
Jun 19
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
437
-1.64%
|
$41,078
$94.63 P/Share
|
|
Jun 10
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,329
-4.43%
|
$132,900
$100.0 P/Share
|
|
May 07
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
393
-1.45%
|
$44,409
$113.67 P/Share
|
|
May 06
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
364
-0.93%
|
$41,132
$113.67 P/Share
|
|
May 06
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
307
-1.12%
|
$34,691
$113.68 P/Share
|
|
May 06
2021
|
Emil D Kakkis President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
852
-0.14%
|
$97,980
$115.71 P/Share
|
|
May 06
2021
|
Thomas Richard Kassberg CBO & EVP |
SELL
Open market or private sale
|
Direct |
363
-0.34%
|
$41,019
$113.69 P/Share
|
|
May 06
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
142
-0.94%
|
$16,046
$113.67 P/Share
|
|
May 06
2021
|
John Richard Pinion |
SELL
Open market or private sale
|
Direct |
363
-0.72%
|
$41,019
$113.69 P/Share
|
|
May 06
2021
|
Karah Herdman Parschauer EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
313
-1.03%
|
$35,369
$113.67 P/Share
|
|
May 06
2021
|
Dennis Karl Huang |
SELL
Open market or private sale
|
Direct |
363
-0.89%
|
$41,019
$113.68 P/Share
|
|
May 03
2021
|
Emil D Kakkis President & CEO |
SELL
Open market or private sale
|
Indirect |
30,000
-1.31%
|
$3,210,000
$107.8 P/Share
|
|
Apr 20
2021
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
396
-1.42%
|
$41,184
$104.28 P/Share
|
|
Apr 16
2021
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,500
+9.07%
|
-
|
|
Apr 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-11.33%
|
$545,000
$109.09 P/Share
|
|
Apr 15
2021
|
Camille L Bedrosian EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.18%
|
$275,000
$55.0 P/Share
|